now disconnect.
Analysts Q&A Summary:
1) Geoff Meacham, Citibank:
– The question: Inquired about the feedback on using sweat chloride as a biomarker for switching from TRIKAFTA to AlifTrex and about chronic pain indications for Gernavix.
– The response: Management stated that sweat chloride is understood in clinical practice more as a measure of CFTR function rather than regularly used. They emphasized Elephtrex’s non-inferiority to TRIKAFTA and its additional benefits. For Gernavix, end of Phase II meeting is on track, with updates expected in the summer.
2) Jessica Fye, JPMorgan:
– The question: Clarified if the tariff impact was from current tariffs or potential new ones and about CF business implications of the Russia issue.
– The response: Management clarified that the current tariff impacts are immaterial due to a geographically diverse supply chain. The Russia issue accounted for a $100 million impact in Q1.
3) Salveen Richter, Goldman Sachs:
– The question: Asked about early adopters of AlifTrex and the nuances of tiered status for Gernavix with commercial payers.
– The response: Uptake for AlifTrex is noted across all patient groups, while for Gernavix, progress with payers is aiming at minimal restrictions and maximizing access.
4) Tazeen Ahmad, Bank of America:
– The question: Requested details on Gernavix patient profiles and settings and expectations for sales acceleration.
– The response: Gernavix is seeing broad use across multiple pain settings, and sales acceleration is expected more in the latter part of the year with coverage advancements.
5) Evan Seigerman, BMO Capital Markets:
– The question: Inquired about barriers to accelerating KASJEVY uptake and solutions.
– The response: Accelerated uptake is due to more treatment centers, improved access and reimbursement, and process familiarity at centers.
6) Michael Yee, Jefferies:
– The question: Concerned potential deceleration of script data for Gernavix and updates on the potency of VX-nine ninety three for pain.
– The response: Management explained initial variability in script data, citing recent growth, and indicates VX-nine ninety three as a more potent option than Gernavix.
7) Lisa Bayko, Evercore ISI:
– The question: Asked about the gross-to-net implications for Gernavix and specific details on zamylosel patient demographics.
– The response: Explained gross-to-net will normalize as access broadens, and zamylosel targets 60,000 severe Type 1 Diabetes patients in phase I.
8) Ellie Merle, UBS:
– The question: Queried about retail pharmacy stocking for Gernavix and comparative settings for scripts.
– The response: Genavix is stocked at about 95% of retail locations, with variable prescription durations around 14 days.
9) David Risinger, Leerink:
– The question: Needed clarification on PBM coverage for Genavix and broader industry engagement in Washington.
– The response: Confirmed PBM figures are included within the total lives covered and highlighted Vertex’s proactive governmental engagements.
10) Gena Wang, Barclays:
– The question: Sought details on the AlifTrex launch compared to historical patterns and more on the temporary pause of VX-five 22.
– The response: AlifTrex uptake is positive across the anticipated patient groups, and temporary study pause details will be shared once more information is available.
Sentiment Score Distribution Table:
| Analyst Name | Firm Name | Sentiment Score (1-10) |
|—————-|————-|————————|
| Geoff Meacham | Citibank | 8 |
| Jessica Fye | JPMorgan | 7 |
| Salveen Richter| Goldman Sachs | 8 |
| Tazeen Ahmad | Bank of America | 7 |
| Evan Seigerman | BMO Capital Markets | 8 |
| Michael Yee | Jefferies | 7 |
| Lisa Bayko | Evercore ISI| 8 |
| Ellie Merle | UBS | 9 |
| David Risinger | Leerink | 8 |
| Gena Wang | Barclays | 7 |